FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/12/2024
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Localização atual
Descrição da marca
The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size.
Titulares
Representantes
Justin R. Young DTL Ltd.
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer
Classe 42
Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
FINAL DECISION TRANSACTION PROCESSED BY IB
07/12/2024
FINAL DISPOSITION NOTICE SENT TO IB
16/11/2024
FINAL DISPOSITION PROCESSED
15/11/2024
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/09/2024
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/06/2024
REGISTERED-PRINCIPAL REGISTER
04/06/2024
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/05/2024
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/04/2024
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
17/04/2024
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/03/2024
PUBLISHED FOR OPPOSITION
19/03/2024
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/02/2024
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/02/2024
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/02/2024
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/02/2024
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/02/2024
APPROVED FOR PUB - PRINCIPAL REGISTER
14/02/2024
EXAMINER'S AMENDMENT ENTERED
14/02/2024
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/02/2024
EXAMINERS AMENDMENT E-MAILED
14/02/2024
EXAMINERS AMENDMENT -WRITTEN
14/02/2024
TEAS/EMAIL CORRESPONDENCE ENTERED
02/02/2024
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/02/2024
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/02/2024
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/01/2024
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/01/2024
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/01/2024
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/01/2024
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/01/2024
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/01/2024
REFUSAL PROCESSED BY IB
28/08/2023
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/08/2023
REFUSAL PROCESSED BY MPU
05/08/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/06/2023
NON-FINAL ACTION WRITTEN
29/06/2023
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
26/06/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/05/2023
NON-FINAL ACTION WRITTEN
16/05/2023
ASSIGNED TO EXAMINER
05/05/2023
APPLICATION FILING RECEIPT MAILED
02/12/2022
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/11/2022
LIMITATION FROM ORIGINAL APPLICATION ENTERED
25/11/2022
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/11/2022
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.